Published in final edited form as:

Ann Surg. 2011 April ; 253(4): 672–683. doi:10.1097/SLA.0b013e318210f3bd.

StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial

John M. Centanni, M.S.^{*}, Joely A. Straseski, Ph.D.[†], April Wicks, B.S.^{*}, Jacquelyn A. Hank, Ph.D.[‡], Cathy A. Rasmussen, Ph.D.^{*,†}, Mary A. Lokuta, Ph.D.^{*}, Michael J. Schurr, M.D.[§], Kevin N. Foster, M.D.[¶], Lee D. Faucher, M.D.[§], Daniel M. Caruso, M.D.[¶], Allen R. Comer, Ph.D.^{*}, and B. Lynn Allen-Hoffmann, Ph.D.^{*,†}

^{*}Stratatech Corporation, Madison, WI, USA

[†]Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA

[‡]Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA

[§]Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA

[¶]Arizona Burn Center at Maricopa Medical Center, Phoenix, AZ, USA

Abstract

Objective—The goal of this study was to assess the immunogenicity and antigenicity of StrataGraft skin tissue in a randomized phase I/II clinical trial for the temporary management of full-thickness skin loss.

Summary Background Data—StrataGraft skin tissue consists of a dermal equivalent containing human dermal fibroblasts and a fully-stratified, biologically active epidermis derived from NIKS cells, a pathogen-free, long-lived, consistent, human keratinocyte progenitor.

Methods—Traumatic skin wounds often require temporary allograft coverage to stabilize the wound bed until autografting is possible. StrataGraft and cadaveric allograft were placed side-by-side on 15 patients with full-thickness skin defects for one week prior to autografting. Allografts were removed from the wound bed and examined for allogeneic immune responses. Immunohistochemistry and indirect immunofluorescence were used to assess tissue structure and cellular composition of allografts. *In vitro* lymphocyte proliferation assays, chromium-release assays, and development of antibodies were used to examine allogeneic responses.

Results—One week after patient exposure to allografts, there were no differences in the numbers of T or B lymphocytes or Langerhans cells present in StrataGraft skin substitute compared to cadaver allograft, the standard of care. Importantly, exposure to StrataGraft skin substitute did not induce the proliferation of patient peripheral blood mononuclear cells to NIKS keratinocytes or enhance cell-mediated lysis of NIKS keratinocytes *in vitro*. Similarly, no evidence of antibody generation targeted to the NIKS keratinocytes was seen.

Conclusions—These findings indicate that StrataGraft tissue is well-tolerated and not acutely immunogenic in patients with traumatic skin wounds. Notably, exposure to StrataGraft did not

Corresponding author / Reprint requests: B. Lynn Allen-Hoffmann, Ph.D., University of Wisconsin-Madison, 5605 Medical Sciences Center, 1300 University Avenue, Madison, WI 53706-1102, Tel: 1-608-262-2884, Fax: 1-608-265-3301, blallenh@wisc.edu.

The first two authors contributed equally to the manuscript.

This study was registered at www.clinicaltrials.gov (NCT00618839).

increase patient sensitivity toward or elicit immune responses against the NIKS keratinocytes. We envision this novel skin tissue technology will be widely used to facilitate the healing of traumatic cutaneous wounds.

INTRODUCTION

Large traumatic cutaneous wounds often result in a life-threatening disruption of barrier function, which necessitates rapid wound closure to prevent dehydration and bacterial infection. Continuous renewal of the epidermis by the interfollicular keratinocyte progenitor cells of the basal layer is crucial for maintenance of the biochemical and mechanical properties of the skin. Based on the pioneering work of Rheinwald and Green,¹ methods have been developed to expand keratinocytes in culture for use in the treatment of severe burns. However, an inherent limitation of the *in vitro* culturing of human keratinocytes is the eventual depletion of the progenitor cell population by serial cultivation.² A consistent source of human epidermal progenitor cells would enable the development of effective treatments for a variety of cutaneous disorders. The previously described NIKS skin cell line is a long-lived, genetically-stable, non-tumorigenic, and pathogen-free human keratinocyte progenitor and is a reliable source as a universal donor.³

In recent years, numerous advances have been made in organotypic culturing systems to generate living bioengineered skin substitutes. By inducing terminal differentiation, these systems are capable of recapitulating many of the structural and functional characteristics of the interfollicular epidermis. Among other features, these tissues form a basement membrane, develop stratified layers which supply protective barrier function, produce growth factors, and secrete host defense peptides.⁴⁻⁷ Despite their therapeutic potential, bioengineered allogeneic tissues have the potential complication of antigenic stimulation of the host immune system. Keratinocytes, the predominant cell type in skin,^{8,9} have historically been considered a passive cellular constituent. Human keratinocytes are classified as “non-professional” antigen presenting cells¹⁰⁻¹² because, although they express major histocompatibility complex (MHC) class I antigens on their cell surface, they lack constitutive expression of MHC class II antigens.^{13, 14} The most widely expressed MHC class II antigen, HLA-DR, as well as the class I antigens HLA-A, -B, and -C are associated with tissue rejection in humans,^{15, 16} and therapeutic outcomes are dramatically improved when these molecules are closely matched between transplant donor and recipient. Within the healthy epidermis, the Langerhans cell is often considered the sole cell type capable of expressing MHC class II and efficiently presenting antigen.¹⁷⁻²⁰ Therefore, engineered skin substitute tissues that do not contain professional antigen presenting cells, such as Langerhans cells or leukocytes, greatly reduce the possibility of allograft antigen presentation.

StrataGraft human skin substitute, produced *in vitro* by the organotypic culture of NIKS keratinocytes, generates a stratified epidermal layer closely resembling that seen in intact human skin. The morphology, differentiation marker expression, basement membrane development, barrier function, and MHC expression of StrataGraft tissue were similar to native human skin, as well as to tissues generated *in vitro* from normal human epidermal keratinocytes (NHEK). StrataGraft was evaluated in a randomized, phase I/II clinical trial as a temporary coverage for patients with full-thickness skin loss of 5% total body surface area (TBSA). In this study, the immunogenicity of StrataGraft skin substitute was examined during an open-label, controlled, randomized, comparative, dose escalation study of the surgical management of complex skin defects in patients undergoing sequential skin reconstruction procedures. The immunological properties of this biological skin substitute were investigated before and after placement in a patient wound. Patient sensitization to the NIKS keratinocytes was also assessed prior to and after placement of StrataGraft tissue by

examining the ability of NIKS cells to induce patient lymphocyte proliferation, the susceptibility of NIKS cells to patient natural killer (NK) cell-mediated lysis, and the development of NIKS-specific antibody responses. Further evaluation included histological examination of the allograft tissues after placement in the wound bed for one week. The results of this study indicate that StrataGraft tissue generated from NIKS keratinocytes has characteristics comparable to skin substitutes prepared from primary NHEK. Furthermore, StrataGraft skin substitute does not induce acute inflammatory responses in patients with full-thickness skin loss. Clinical assessment of the StrataGraft-treated wound beds indicated that StrataGraft skin tissue offers an innovative therapeutic solution for acute skin defects and will likely continue to function beyond the time frame investigated.²¹ Phase II proof of concept studies investigating longer exposure to StrataGraft are warranted given the safety results obtained during this study.

METHODS

Monolayer and organotypic culture

Human neonatal foreskin tissue was obtained by informed consent in accordance with both Meriter Hospital (Madison, WI) and the University of Wisconsin-Madison Institutional Review Boards (IRBs). A description of the cell culture and tissue production is available online (Supplemental digital content 1).

Study enrollment

A phase I/II, multi-center, open-label, randomized, safety and dose escalation trial was conducted from 2007 to 2008 under a clinical protocol on file with Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA). The study was performed to assess autograft take and infection in 15 patients with full-thickness skin defects, who were intended to undergo sequential surgical procedures involving surgical skin debridement and temporary cadaver allograft placement followed by autografting.²¹ The trial was conducted at the University of Wisconsin Hospital and Clinics (Madison, WI) and the Arizona Burn Center at Maricopa Medical Center (Phoenix, AZ) and funded in part by the National Institutes of Health. The patients enrolled in this study had wounds resulting from thermal burns (n=11), surgical resection of soft tissue infection (n=2), electrical burns (n=1), and traumatic injury (n=1). Mean patient age was 43.4 ± 14.7 years; 73.3% of the patients were male, and the mean full-thickness skin loss was $22.2\% \text{ TBSA} \pm 18.0$.

Declaration of Helsinki, Informed Consent, and HIPAA statement

This trial was conducted in accordance with good clinical practices and FDA regulations and guidelines. These regulations and guidelines encompass all principles established by the Declaration of Helsinki and all its subsequent amendments. The research protocol and informed consent forms were approved by the respective IRB for each participating study site. The consent form was available in English and Spanish as needed. At the time of enrollment, all patients were assigned a sequential, de-identified number and clinical study site identifier. For the purposes of maintaining patient anonymity and to eliminate bias, all patient samples and representative photos were labeled with the coded patient number and the blinded wound site designation.

Patient Treatment and Study Design

Treatment for each wound site was randomized such that one half of a contiguous wound site received StrataGraft skin substitute and the other adjacent half received the standard of care, banked, cryopreserved, cadaver allograft.²¹ The allogeneic skin treatments were applied to the debrided wound site. Allografts were placed and secured with staples,

photographed, and covered with non-adherent petrolatum impregnated gauze. Wound dressings were changed approximately every two days until allograft removal. Assessments were performed during each dressing change for allograft adherence, color, and visual signs of infection. One week after placement, the StrataGraft and cadaver allografts were removed. Subsequent autograft placement occurred when the wound bed was judged by the physician to be suitable to accept an autograft. Autografts were likewise covered with non-adherent petrolatum impregnated gauze and dressings were changed at days 3, 6 and then daily until healed. Autografts were monitored for adherence, color, autograft take, and visual signs of infection. As additional patients were enrolled, the targeted dose of StrataGraft tissue was sequentially increased. The first 5 patients were treated with no more than 0.5% TBSA of StrataGraft skin substitute. The second cohort of 5 patients was treated with up to 1.0% TBSA of StrataGraft tissue. The third patient cohort was treated with no more than 1.5% TBSA of StrataGraft skin substitute.

Clinical and Laboratory Tests

Clinical and laboratory tests for the clinical trial patients were performed as described.²¹

Study Endpoints

The primary safety and efficacy outcome was the percentage of autograft take, assessed by the study team, two weeks after autograft placement. Additional safety and efficacy assessments included immunohistochemical (IHC) and indirect immunofluorescent (IIF) evaluations of allograft tissues after their removal from the wound site. Systemic immune responses were evaluated using panel reactive antibody (PRA) assessment, mixed leukocyte reactions (MLR), and ⁵¹Chromium-release cytotoxicity (CTL) assays.

Histology

The histologic preparation and staining procedures of the tissue samples were performed using standard methods and are described in detail online (Supplemental digital content 1).

PBMC Functional Assays

PBMC purification and cellular activation assays were performed by standard methods and a complete description can be found online (Supplemental digital content 1).

RESULTS

NIKS keratinocytes produce a morphologically accurate stratified squamous epithelial tissue

Using histology and indirect immunofluorescence (IIF), the structure and differentiation state of tissues generated from primary NHEK or from NIKS keratinocytes were examined and compared to native human skin tissue. Hematoxylin and eosin (H&E) staining revealed that the epidermal morphology of tissues made from NIKS cells was indistinguishable from that of tissue prepared with NHEK (Figure 1A). All tissues contained a distinct basal layer consisting of cuboidal cells with a high nucleus-to-cytoplasm ratio. Cells within the spinous layer exhibited flattening typical of terminal epidermal differentiation. Distinct staining of keratohyalin granules within the granular layer was evident in all tissues, as was a well-defined enucleated stratum corneum, both characteristic of mature epidermis. Each of these histological features was also present in native skin which typically exhibits a thinner stratum corneum as a result of friction and sloughing.

The ability of NIKS and NHEK organotypic cultures to generate a functional barrier was assessed by measuring skin surface electrical impedance (SEI). The rate of SEI change

correlates with the rate of transepidermal water loss, indicating the integrity of the epidermal permeability barrier.^{22, 23} Both NIKS and NHEK produced tissue with barrier function that was comparable to intact human forearm skin (Figure 1B). In contrast, loss of barrier function was readily detectable using SEI after tape stripping of human forearm skin.

Markers of keratinocyte differentiation were visualized by IIF to evaluate cellular differentiation and tissue morphogenesis. Staining for the membrane-bound intermediate-stage differentiation marker type I transglutaminase (TG) was seen in the suprabasal layers of both NIKS and NHEK tissues, continuing up to the stratum corneum (Figure 1C). Likewise, TG staining in native foreskin tissue was membrane-bound and located only within the mature epidermal layers. Expression of filaggrin, a marker of intermediate-to-late stage keratinocyte differentiation, was appropriately contained within the granular layer of both NIKS and NHEK tissues, similar to that seen in native skin. Additional markers of stratified squamous epithelia differentiation including involucrin, structural proteins keratin 1, keratin 14 and keratin 2, as well as the cell adhesion proteins E- and P-cadherin, were assessed and exhibited appropriate localization in NIKS and NHEK tissues (data not shown).

Collagen IV was detected by IIF to investigate basement membrane formation in tissues generated *in vitro*, (Figure 1C). All tissues showed appropriate deposition of collagen IV at the epidermal-dermal junction. Staining was varied throughout the length of the tissue, revealing both focal and diffuse staining patterns. In foreskin tissue, collagen IV staining was present at the epidermal-dermal junction with additional localization to the interface of resident hair follicles in the dermis. These data demonstrate that NIKS keratinocytes terminally differentiate in organotypic culture to form a mature, fully differentiated, and biologically functional tissue which possesses barrier function comparable to that of intact human skin.

NIKS and primary keratinocytes express similar levels of immunological cell markers

To determine the baseline immunophenotypic characteristics of NIKS tissue, the expression of several cell surface molecules which are involved in immune responses was examined. Immunofluorescence was used to detect the MHC class I human leukocyte antigen complex (HLA-ABC), the most abundant class II antigen (HLA-DR), and the co-stimulatory molecules B7-1, B7-2 and CD40. Positive staining for HLA-ABC was detected in the basal and immediately suprabasal layers of NIKS and NHEK tissues (Figure 1D). In native neonatal foreskin tissue, expression of HLA-ABC antigen was present in basal and additional suprabasal layers. HLA-ABC staining was appropriately localized to the cell membrane in all tissues.

Keratinocytes do not constitutively express MHC class II or co-stimulatory molecules on their surface and are therefore categorized as non-professional antigen presenting cells. As expected, both NIKS and NHEK tissues were negative for HLA-DR antigen staining (Figure 1D). In contrast, HLA-DR expression was apparent in both the dermal and epidermal compartments of native foreskin, with cellular morphology indicative of dendritic cell or leukocytic expression and not keratinocyte expression. Expression of the co-stimulatory molecules B7-1, B7-2, and CD40 was not detectable in NIKS, NHEK, or native foreskin tissues (data not shown). These data suggest that although NIKS cells will likely be recognized as allogeneic by the immunocompetent host through the expression of class I antigens, they lack any constitutive antigen presentation capability.

StrataGraft human skin substitute maintained normal tissue architecture and remained viable after one week in the patient wound bed

StrataGraft skin substitute, which is produced using NIKS keratinocytes, was compared to cryopreserved cadaver allograft, the standard of care, in the conditioning of debrided, full-thickness wounds prior to autograft placement. A phase I/II, randomized, controlled, safety and dose escalation trial was conducted in 15 patients whose wounds prior to autografting were temporarily covered with StrataGraft and cadaver allografts in a randomized, split-wound format. The primary safety and efficacy outcomes of this trial were recently published²¹ and demonstrate that StrataGraft was well-tolerated and comparable to the standard of care in the surgical management of large full-thickness skin defects. No evidence of product related adverse events was seen. Figure 2 summarizes the study design and major evaluation points and immunological assessments. Allografts were removed from the wound beds one week after placement and samples were fixed, sectioned, and stained to assess tissue structure, composition, and proliferative capacity. Histological analysis of both StrataGraft and cadaver allografts confirmed that the tissue morphology and stratification remained intact during the one week placement period (Figure 3). Specifically, a single basal layer of cuboidal cells was observed in both StrataGraft and cadaver allograft tissue. Likewise, the spinous and granular layers, as well as the stratum corneum, were evident in both StrataGraft and cadaver allograft tissues after removal from the wounds.

Immunohistochemical (IHC) staining for Ki67, a protein expressed only in proliferating cells²⁴, was used as an indicator of allograft viability. StrataGraft samples consistently exhibited Ki67 staining in both basal and suprabasal keratinocytes (Figure 3B) as has been shown previously in native human skin during wound healing.²⁵ Cadaver allograft samples exhibited Ki67 staining almost exclusively in the basal cell layer, although the percentage of positive cells was highly variable (Figure 3B). Two blinded observers each scored at least 400 cells from each sample as either positive or negative for Ki67 staining and the ratio of stained:total cells was reported as the proliferation index (PI). Intensity of staining was not considered in this evaluation. Although not statistically significant using a paired, two-tailed Student's *t*-test and a 95% confidence interval ($p=0.110$), the mean PI of StrataGraft tissue was higher (0.521) than that of cryopreserved cadaver allograft (0.288). The median value for StrataGraft skin tissue was 0.567 as compared to 0.189 for cadaver skin (Figure 3C). Furthermore, the range of values for StrataGraft (0.523) was approximately half that for cadaver skin (0.944), suggesting that StrataGraft is a more consistent source of viable and biologically active cells for the conditioning and coverage of cutaneous wounds.

StrataGraft skin tissue did not induce acute inflammatory infiltrate *in vivo*

Infiltration of T lymphocytes, B lymphocytes, and Langerhans cells into StrataGraft and cadaver allografts was assessed as an indicator of allograft antigenicity and early graft rejection. Samples were assessed for immunohistochemical staining of the T cell marker CD3. Modest numbers of T cells were found in either the epidermal or dermal compartments of the allografts (Figure 4). Scoring by two independent blinded observers revealed no statistically significant differences in the numbers of CD3 positive cells in the dermis and epidermis of StrataGraft skin substitute compared to cadaver allograft. Staining for the B cell marker CD20 revealed few, if any, CD20 positive cells in and around the epidermis of either allograft (Figure 4). Occasional samples contained significant B cell infiltrate in the wound bed material adjacent to the allografts; however, no statistically significant differences between StrataGraft and cadaver allografts were seen. The presence of Langerhans cells in the epidermis of StrataGraft and cadaver allografts was assessed by immunohistochemical staining of CD1a. CD1a positive cells were observed in both StrataGraft and cadaver allograft (Figure 4); however no statistically significant differences in cell numbers were detected. Taken together, these data show that after placement of

StrataGraft skin substitute for one week in full-thickness wounds normal tissue architecture is maintained with no substantial infiltration of lymphocytes. These data suggest that StrataGraft skin substitute does not induce an acute inflammatory response in patients with traumatic skin loss.

MHC class I but not class II expression was detected in epidermal layers after placement in full-thickness wounds

After placement in full-thickness wounds for one week, StrataGraft and cadaver allografts were assessed for HLA-ABC and HLA-DR staining as indicators of early graft rejection, inflammation, tissue antigenicity, and epidermal reactivity. Evaluation was based on the presence and localization of staining, rather than intensity. HLA-ABC expression within StrataGraft and cadaver allografts was membrane-localized and present in the majority of stratified keratinocyte layers (Figure 5A). This staining pattern is unlike the expression seen in ungrafted tissues which was restricted to the basal and immediately suprabasal layers (Figure 1D). Few HLA-DR positive cells were observed within the epidermis of either StrataGraft or cadaver allografts (Figure 5B). Cells that expressed HLA-DR were found predominantly within the dermis with little infiltration into the epidermal portion of the allografts. The morphology of the few HLA-DR positive cells within the epidermis was suggestive of dendritic cells and not of keratinocytes. Localization of HLA-DR staining was similar between StrataGraft tissue and cadaver skin. These data indicate that the allogeneic keratinocytes of StrataGraft or cadaver skin did not exhibit detectable expression of HLA-DR after one week in the wound bed as might be seen during an acute inflammatory response.

Tissues generated from NIKS and primary NHEK regulate immunological markers similarly in response to γ -interferon (IFN- γ) stimulation *in vitro*

Previous work *in vitro* has shown that NHEK express HLA-DR and CD40 upon exposure to the pro-inflammatory cytokine IFN- γ .^{11, 26-34} However, even after IFN- γ treatment, primary keratinocytes do not express the co-stimulatory molecules B7-1 or B7-2 at levels sufficient to induce T cell proliferation.^{26, 27} In order to confirm that the lack of inflammatory infiltrate seen in the clinical samples was not the result of a defect in the cellular response to stimulation, immunofluorescence was used to determine whether StrataGraft upregulated these immunological markers in response to cytokine stimulation. Tissues were treated *in vitro* with 50, 100 or 1000 units/mL of recombinant human IFN- γ (rhIFN- γ) for 5 days. StrataGraft showed enhanced membranous expression of the MHC class I antigens, HLA-ABC, following IFN- γ exposure (See Figure, Supplemental digital content 2). At all IFN- γ doses, HLA-ABC was detected in the majority of the stratified keratinocyte layers whereas the vehicle control tissues exhibited HLA-ABC expression which was restricted to the basal and immediately suprabasal layers.

After treatment with rhIFN- γ , HLA-DR expression was detectable in the cell membranes of both basal and immediately suprabasal NIKS cells (See Figure, Supplemental digital content 2). Moreover, there was a dose dependent increase in the number of tissue layers expressing HLA-DR antigen. IFN- γ -treatment of NIKS tissues also induced a dose-dependent increase in the expression of CD40, although expression was restricted to the basal layer even at the highest dose of IFN- γ (See Figure, Supplemental digital content 2). NIKS tissues did not exhibit detectable levels of B7-1 or B7-2 even when exposed to high levels of rhIFN- γ (1000 U/mL, See Figure, Supplemental digital content 2). NHEK tissues showed a similar dose-dependent increase of HLA-ABC, HLA-DR, and CD40 expression with no detectable B7-1 or B7-2 expression after exposure to rhIFN- γ (data not shown). No changes in localization or staining intensity of the keratinocyte differentiation markers TG, filaggrin, involucrin, E- and P-cadherin, keratins 1, 14 and 2 were observed in IFN- γ -treated NIKS or

NHEK tissues when compared to vehicle controls (Supplemental digital content 3 and data not shown). These data indicate that NIKS keratinocytes are capable of expressing MHC class II on their surface. However, NIKS keratinocytes do not express detectable B7-1 or B7-2 after IFN- γ stimulation, suggesting that they would be unlikely to act as antigen presenting cells and activate acute T lymphocyte responses directly.

PBMC from clinical trial patients did not exhibit increased responsiveness against NIKS keratinocytes after exposure to StrataGraft tissue

In order to determine whether exposure to StrataGraft tissue increased the numbers of patient white blood cells specific for NIKS keratinocytes, *in vitro* cellular proliferation assays were performed. Patient peripheral blood mononuclear cells (PBMC) were assessed in a cellular proliferation assay both at baseline (pretreatment) and again at the time of allograft removal (post-treatment). Proliferation assays were carried out for 3 days and 6 days and the stimulation index (SI = counts per treatment / counts in media control) calculated. The mean baseline value for patient PBMC cultured with medium for 6 days was 1738 ± 2906 counts (SI=1). There was a significant increase in the mean value for baseline patient PBMC stimulated with the positive control phytohemagglutinin (PHA) (SI=22.8; $p < 0.0001$). Baseline PBMC did not proliferate in response to irradiated autologous PBMC (SI=1.13). As expected, there was a reproducible increase in counts to irradiated allogeneic PBMC (SI=9.05; $p < 0.0001$), however, no increase in proliferation was seen with the irradiated NIKS cells at 1×10^5 (SI=0.266) or 1×10^4 (SI=0.395) cells per well.

Mean sample values for patient PBMC obtained after allograft removal were similar to those with PBMC obtained at baseline. Responses to PHA and irradiated allogeneic PBMC after allograft placement (SI=10.05 and SI=6.21 respectively) were comparable to those seen at baseline ($p=0.21$ and $p=1.00$ respectively). The mean responses of patient PBMC to irradiated NIKS cells before and after treatment was not statistically significant (SI=0.225 and 0.492 respectively; $p=0.80$). The patient-specific SI values for PBMC co-cultured with irradiated NIKS cells are shown in Table 1 and indicate a lack of allogeneic sensitization against the NIKS keratinocytes. There were no significant changes between the baseline and post-treatment responses in the 3 day or 6 day assays (Table 1 and data not shown). Likewise, there were no differences in any values obtained from the three patient cohorts.

To test whether the lack of PBMC responsiveness was due to reduced immunocompetency in the patient population, *in vitro* cellular proliferation assays were performed to determine whether allogeneic NIKS keratinocytes induced the proliferation of PBMC from healthy individuals. PBMC isolated from healthy, immunocompetent donors were co-cultured with irradiated NIKS keratinocytes. PBMC proliferation was not stimulated by irradiated allogeneic NIKS cells (See Table, Supplemental digital content 4). In order to account for any inhibitors of proliferation that may be produced by the NIKS cells, serial 10-fold dilutions of NIKS keratinocytes from 1×10^5 to 1×10^2 cells per well were also tested with similar results (See Table, Supplemental digital content 4, and data not shown). Comparable data were obtained with PBMC from a total of 4 human volunteers over 10 replicate experiments. These *in vitro* proliferation data suggest that the placement of StrataGraft skin tissue in a wound bed does not enhance patient PBMC activation toward NIKS or allogeneic PBMC. Further, these data indicate that patient PBMC obtained following StrataGraft tissue placement do not have an altered proliferative response compared with that prior to allograft placement. Taken together, these data suggest that NIKS keratinocytes do not induce the activation of PBMC directly.

Patient PBMC exhibited minimal NK cell-mediated killing of NIKS cells *in vitro*

Patient PBMC obtained at study entry (pretreatment) or at the time of allograft removal (post-treatment) were tested in an *in vitro* cytotoxicity assay to assess the level of NK cell activity toward NIKS keratinocytes (Table 2) and the NK-sensitive cell line K562. Patient PBMC mediated only low level cytolytic activity against the K562 targets at all effector:target (E:T) ratios tested and there was no significant difference in the cytotoxicity seen with PBMC obtained at baseline as compared to those obtained following allograft exposure. At the 50:1 E:T ratio, mean patient cytotoxicities toward K562 cells were $13.10\% \pm 9.48$ pretreatment and $11.09\% \pm 10.15$ post-treatment (n=13). NIKS keratinocytes used as target cells were relatively NK cell-resistant and patient PBMC obtained prior to StrataGraft placement exhibited little lytic activity toward them at all E:T ratios tested (mean patient cytotoxicity $7.68\% \pm 9.58$ for 50:1 E:T; n=14). To ensure that the apparent resistance of NIKS cells to NK cell killing was not the result of a potentially immunocompromised patient population, the spontaneous lytic activity of NK effector cells against NIKS keratinocytes was assessed. PBMC from healthy donors were cultured with ^{51}Cr -labeled target cells; either the allogeneic NIKS keratinocytes or the positive control, NK cell-sensitive, MHC class I^{low}, leukemia cell line K562. Quadruplicate assays were performed on PBMC from 4 human volunteers in over 10 replicate experiments with similar results. No cellular lysis resulted from co-culturing the NIKS keratinocytes with healthy donor effector PBMC suggesting that NIKS cells are inefficient NK cell targets (See Table, Supplemental digital content 5).

At the time of allograft removal, patient PBMC did not exhibit enhanced lytic activity at any E:T ratio when compared to baseline values ($9.03\% \pm 12.26$ for 50:1 E:T; n=14). These *in vitro* cytotoxicity data suggest that the exposure of patients to StrataGraft skin substitute for one week did not induce *in vivo* priming of patient PBMC NK cell lytic activity against NIKS cells *in vitro*. Significantly, the PBMC obtained following allograft placement did not have an altered response from the PBMC obtained prior to allograft placement.

Clinical trial patients did not develop antibody responses targeted to the HLA types of NIKS cells

To assess the development and specificities of antibodies directed against MHC antigens by study participants, panel reactive antibody (PRA) levels were measured prior to allograft placement, at the time of allograft removal (~7 days), and again at the study completion (~90 days; Table 3). It is important to note that most of the patients received blood product transfusions during the study and all patients were exposed not only to the StrataGraft skin substitute (0.3-1.5 %TBSA), but also to cryopreserved cadaveric allografts (4.4-72.1 %TBSA). Six of the fifteen patients exhibited elevated PRA values for at least one time point; however, all of these patients exhibited reactivities to HLA antigens that are absent on both NIKS cells and the dermal fibroblasts of the StrataGraft® tissue. Five of these six patients received blood product transfusions during the study, one patient had an infection in the wound bed at the time of allograft removal, and the full-thickness wounds in two of these patients were the result of necrotizing fasciitis. Patient 4 developed antibodies to a single HLA allele expressed by NIKS keratinocytes; however, it is unlikely that this reactivity was a targeted response to the StrataGraft skin substitute since that individual also developed antibody specificities against other HLA alleles not expressed in StrataGraft tissue and did not develop additional reactivities to other HLA antigens on the NIKS keratinocytes. It is also important to note that this individual not only had an elevated baseline PRA value but was also in the low dose StrataGraft tissue group. These data indicate that StrataGraft human skin substitute is not acutely antigenic and does not elicit a potent antibody response.

DISCUSSION

We have recently reported data from this phase I/II randomized safety and dose escalation clinical trial showing that StrataGraft skin substitute is well tolerated and comparable to cadaver allograft in the temporary treatment of debrided wounds prior to autograft placement²¹. This living skin substitute, composed of the NIKS keratinocyte progenitor cell line, was equivalent to cadaver skin in terms of wound bed preparation and did not increase the incidence of wound infection in this patient population. This data, in conjunction with the data presented here, illustrate the clinical utility of StrataGraft skin substitute as a pathogen-free, universal source of human skin in the temporary management of full-thickness skin wounds of several etiologies. As a non-tumorigenic source of long-lived, genetically identical keratinocytes, use of the NIKS keratinocyte cell line is advantageous when compared with other primary keratinocyte samples which senesce after multiple passages. The work described here characterizing the antigenic properties of StrataGraft skin substitute before and after patient exposure supports the continued clinical development of this biologically active skin tissue. The major findings in this study are that StrataGraft skin substitute maintains normal tissue architecture, remains viable after one week in acute, full-thickness wounds, is well tolerated by recipients, and does not induce an acute immune response.

After removal from the patient wound bed the epidermal stratification of the StrataGraft remained intact. A single layer of cuboidal basal cells with suprabasal spinous, granular, and cornified layers were evident in the tissues post-placement, suggesting a lack of acute immune response to and resultant tissue destruction of the allografts. Additionally, keratinocytes within the basal compartment of the stratified tissue stained positively for the cell cycle protein Ki67. Expression of Ki67 has been used as an indicator of keratinocyte proliferation and increases during wound healing.^{24, 35} Normal proliferative indices (PI; stained cells:total cells) vary based on numerous factors including the anatomical location of the skin and the age of the individual.^{36, 37} The data shown here indicate that the PI values for StrataGraft skin substitute are more uniform than those for cryopreserved cadaver allograft. These data suggest that StrataGraft is a more consistent source of viable keratinocytes which will respond reliably within the context of a wound bed.

Although they could be found in the wound bed, T cells were only occasionally seen in close apposition to the epidermis, further suggestive of a lack of antigenicity of the allograft. Limited evidence of B lymphocytes in or around the epidermal layers was observed. The significance of Langerhans cells (LC) in the epidermis of both StrataGraft and cadaver allograft tissues after placement in the wound bed is unclear. Historically, LC have been thought to play a role in graft rejection since they express MHC class II and are potent APC.³⁸ However, recent work has suggested that LC may be important in the development of immunological tolerance.³⁹ While the exact role that LC play during transplantation may still be debated, it is clear that these cells traffic rapidly into and out of the skin and their presence in StrataGraft skin substitute indicates that StrataGraft tissue readily allows cellular trafficking. In sum, there was no evidence of rapid infiltration of leukocytes including T and B lymphocytes nor was there evidence of rapid destruction of the allograft architecture which is seen when there is significant neutrophilic or mononuclear cell influx and activation seen during acute inflammatory responses. Over the years, many studies have been focused on determining the immunogenic elements of allogeneic tissue responsible for acute graft rejection. Studies have shown that passenger leukocytes are largely responsible for this response^{40, 41} and that the rejection of transplanted tissues can take place either directly or indirectly. Acute rejection most often occurs as a result of direct allorecognition in which intact MHC class I and II molecules on the allografted tissue are recognized by the recipient T cells. This type of direct response tends to be quite rapid and the transplanted

tissue is quickly recognized, infiltrated by recipient leukocytes, and broken down. Indirect allorecognition occurs when transplanted donor cells die and their MHC class I or II molecules are processed and presented on the recipient antigen presenting cells (APC). This type of alloresponse tends to occur more slowly and has been shown to play a primary role in chronic tissue rejection as well as a lesser role in acute immune reactions.^{42, 43} Previous work has shown that the incubation of allogeneic human tissue *in vitro* prior to transplantation reduces its immunogenicity. This is likely due to the death of passenger leukocytes during the culturing period, which reduces or eliminates acute allorecognition responses.⁴⁴⁻⁴⁶ StrataGraft skin substitute does not contain leukocytes or dendritic cells and is therefore does not generate a direct alloresponse in the recipient.

Human skin is constantly exposed to a tremendous number of environmental antigens and the presence of immunological markers on the keratinocyte surface is directly affected by the microenvironment in which these cells exist. Once a cutaneous wound has occurred, the milieu of pro-inflammatory cytokines may provoke keratinocytes to become active participants in the cutaneous immune response. The expression of MHC class I and class II antigens, in particular, HLA-A, -B, and -DR, have been closely associated with tissue rejection in humans.^{15, 16} The ability of keratinocytes to present antigen to CD4⁺ T cells is tightly controlled through the regulated expression of HLA-DR and essential co-stimulatory molecules on their surface. Previous work has shown that the potent pro-inflammatory cytokine IFN- γ is able to induce HLA-DR expression in keratinocytes within a cultured skin substitute.⁴⁷ The data presented here indicate that both NIKS and primary NHEK tissues lack constitutive expression of the MHC class II antigen HLA-DR. *In vitro* exposure of the tissues to IFN- γ was sufficient to enhance the expression of HLA-ABC and induce the expression of HLA-DR and the co-stimulatory molecule, CD40, similar to that seen in other skin substitutes.⁴⁷ However, even at high concentrations of IFN- γ , expression of the key co-stimulatory molecules B7-1 or B7-2 was not detected.

In contrast to what one may anticipate during an acute inflammatory response and unlike that seen in animal models of skin grafting^{48, 49}, placement of StrataGraft skin substitute in acute full-thickness wounds in human patients is not sufficient to induce the expression of HLA-DR on the allografted keratinocytes. The HLA-DR expression seen in the tissues was instead suggestive of the presence of dendritic cells and leukocytes. This lack of HLA-DR expression by the keratinocytes coupled with the lack of induction of key co-stimulatory molecules supports similar findings in the literature and suggests that NIKS cells are incapable of delivering the co-stimulatory “second signal” essential for activating T cells even in the presence of IFN- γ .⁵⁰⁻⁵² Furthermore, this result is in agreement with clinical studies of other skin substitutes which indicate a lack of clinical rejection.⁵³⁻⁵⁵ Several cutaneous skin disorders are associated with aberrant expression of HLA-DR on the keratinocyte surface, leading to increased infiltration of inflammatory cells.^{56, 57} The results presented here indicate that NIKS cells do not express HLA-DR after placement in acute wounds and are therefore unlikely to act as antigen presenting cells leading to acute rejection and enhanced inflammatory responses.

While this study did not investigate the role of minor histocompatibility antigens, the inability of NIKS keratinocytes to induce expression of co-stimulatory molecules most likely limits their ability to engage in functional T cell stimulation and induce direct allorecognition. However, indirect allorecognition is an ongoing process due to the continual trafficking of recipient APC through the graft and the turnover of allograft cells. Our data indicate that after placement in full-thickness skin wounds, HLA-ABC was expressed in the majority of stratified keratinocyte layers. We therefore anticipate that like other allogeneic skin substitutes, StrataGraft tissue will not persist permanently on an immunocompetent recipient but will be slowly replaced as the patient's own keratinocytes are able to

proliferate and fill in. This is in agreement with previous studies of the Apligraf skin substitute, which showed that it does not permanently engraft and is undetectable after 2-3 months.⁵⁸⁻⁶¹

Results from *in vitro* cellular assays indicated that the patients enrolled in this trial did not develop enhanced proliferative responses to NIKS cells or to allogeneic PBMC after exposure to StrataGraft skin substitute. These data support the conclusion that exposure to StrataGraft tissue does not prime the patient PBMC *in vivo*. Likewise, no evidence of NIKS-directed cytotoxicity after exposure to StrataGraft tissue was found. It is well established that susceptibility to NK cell lysis is inversely proportional to MHC class I molecule expression on target cells⁶²⁻⁶⁵, thus the presence of HLA-ABC molecules on NIKS keratinocytes likely provides protection from cellular lysis by NK cells.^{66, 67} It is likely that the constitutive presence of MHC class I molecules and the lack of MHC class II and co-stimulatory molecules reduces the recognition of the allogeneic NIKS keratinocytes as foreign by the patient immune system. In addition, no correlation was observed between increased StrataGraft skin substitute dose and elevated PRA values, nor did patients develop antibody responses to cells of the StrataGraft skin substitute. These *in vitro* functional assays are indicative of a lack of recipient sensitization to or acute rejection of StrataGraft skin substitute tissue.

Composite human skin substitutes such as those created using the organotypic culturing method outlined here have been suggested to be immunologically neutral, thus providing promise for their acceptability in a grafting environment.^{50, 55, 68, 69} While LC are considered the primary APC within cutaneous tissues, it has been established that endothelial cells are also capable of presenting antigen.⁷⁰ The tissues described here are devoid of these cell types. Furthermore, we have shown that NIKS keratinocytes do not upregulate co-stimulatory molecules B7-1 and B7-2, thus limiting the possibility of successful T cell activation even in the presence of inflammatory signals such as those found in the wound environment. Beyond IFN- γ , other immunoregulatory cytokines including IL-1 α , IL-6 and IL-12 are insufficient to elicit an alloresponse against NHEK or dermal fibroblasts in functional *in vitro* assays, further suggestive that keratinocytes can generate an inert skin substitute.⁴⁷ StrataGraft skin substitute has unique qualities that make it an invaluable resource for use in epidermal development, tissue engineering and transplantation studies. The work presented here shows that StrataGraft tissue generated from NIKS keratinocytes is well tolerated, and does not elicit an acute immune response in human graft recipients. These findings further substantiate the utility of this unique cell-based product for therapeutic applications in the treatment of cutaneous wounds and disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to acknowledge the dedicated nursing and research study staff including Cindy Schmitz, RN, Deborah Gawin, Janice Yakey at the University of Wisconsin-Hospital and Clinics, and Karen Richey at the Arizona Burn Center at Maricopa Medical Center. We greatly appreciate Bryan Becker, MD and William Busse, MD for their useful discussions. We would also like to thank Alejandro Munoz, PhD, Victoria Rajamanickam, PhD, and Jens Eickhoff, PhD for their assistance with the statistical analyses, Andreas Friedl, MD for histologic analysis, and Ms. Ellen Mast for assistance with indirect immunofluorescent staining.

Funding:

This research was funded by the following grants:

Howard Hughes Medical Institute (MJS and LAH)

Stratatech Corporation

University of Wisconsin Department of Surgery (MJS)

NIH/NIAMS R43-AR47499 (ARC)

NIH/NHLBI R01-HL74284 (LAH)

NIH/NIAMS R41-AR050349 (LAH)

NIH/NIAMS R42-AR050349 (LAH)

NIH/NIAMS R44-AR47499 translational clinical grant (ARC)

Abbreviations

APC	antigen presenting cells
E:T	effector:target
IFN-γ	γ -interferon
H&E	hematoxylin and eosin;
HLA	human leukocyte antigen complex
IHC	immunohistochemical
IIF	indirect immunofluorescence
LC	Langerhans cells
MHC	major histocompatibility complex
NK	natural killer
NHEK	normal human epidermal keratinocytes
PRA	panel reactive antibody
PBMC	peripheral blood mononuclear cells
PHA	phytohemagglutinin
PI	proliferation index
SI	stimulation index
SEI	surface electrical impedance
TBSA	total body surface area
TG	transglutaminase

REFERENCES

1. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell*. 1975; 6(3):331–43. [PubMed: 1052771]
2. Barrandon Y, Green H. Three clonal types of keratinocyte with different capacities for multiplication. *Proc Natl Acad Sci U S A*. 1987; 84(8):2302–6. [PubMed: 2436229]
3. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, et al. Normal Growth and Differentiation in a Spontaneously Immortalized Near-Diploid Human Keratinocyte Cell Line, NIKS. *Journal of Investigative Dermatology*. 2000; 114(3):444–455. [PubMed: 10692102]

4. Hrabchak C, Flynn L, Woodhouse KA. Biological skin substitutes for wound cover and closure. *Expert Rev Med Devices*. 2006; 3(3):373–85. [PubMed: 16681458]
5. Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. *Tissue Eng*. 2006; 12(9):2407–24. [PubMed: 16995775]
6. Eisenbud D, Huang N, Luke S, Silberklang M. Skin Substitutes and Wound Healing: Current Status and Challenges. *Wounds*. 2004; 16(1):2–17.
7. MacNeil S. Progress and opportunities for tissue-engineered skin. *Nature*. 2007; 445(7130):874–80. [PubMed: 17314974]
8. Passeron T, Coelho SG, Miyamura Y, et al. Immunohistochemistry and in situ hybridization in the study of human skin melanocytes. *Exp Dermatol*. 2007; 16(3):162–70. [PubMed: 17286807]
9. From somatic cells to pluripotent stem cells. *BioProbes*. 2010; 62:13–15.
10. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC Class II antigens in normal human organs. *Transplantation*. 1984; 38(3):293–8. [PubMed: 6591602]
11. Wikner NE, Huff JC, Norris DA, et al. Study of HLA-DR synthesis in cultured human keratinocytes. *J Invest Dermatol*. 1986; 87(5):559–64. [PubMed: 3095434]
12. Morhenn VB, Benike CJ, Cox AJ, et al. Cultured human epidermal cells do not synthesize HLA-DR. *J Invest Dermatol*. 1982; 78(1):32–7. [PubMed: 7033395]
13. Barnstable CJ, Jones EA, Crumpton MJ. Isolation, structure and genetics of HLA-A, -B, -C and -DRw (Ia) antigens. *Br Med Bull*. 1978; 34(3):241–6. [PubMed: 82461]
14. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. *Transplantation*. 1984; 38(3):287–92. [PubMed: 6591601]
15. Dausset J, Contu L, Legrand L, Rapaport FT. The role of HLA-DR antigens in transplantation--survival of skin allografts in HLA-haploidentical donor-recipient combinations. *Transplant Proc*. 1978; 10(4):995–9. [PubMed: 366837]
16. Jonker M, Hoogbeem J, van Leeuwen A, et al. Influence of matching for HLA-DR antigens on skin graft survival. *Transplantation*. 1979; 27(2):91–4. [PubMed: 380076]
17. Stingl G, Tamaki K, Katz SI. Origin and function of epidermal Langerhans cells. *Immunol Rev*. 1980; 53:149–74. [PubMed: 6162777]
18. Teunissen MB. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. *Histochem J*. 1992; 24(10):697–716. [PubMed: 1428996]
19. Klareskog L, Tjernlund U, Forsum U, Peterson PA. Epidermal Langerhans cells express Ia antigens. *Nature*. 1977; 268(5617):248–50. [PubMed: 329142]
20. Rowden G, Lewis MG, Sullivan AK. Ia antigen expression on human epidermal Langerhans cells. *Nature*. 1977; 268(5617):247–8. [PubMed: 329141]
21. Schurr MJ, Foster KN, Centanni JM, et al. Phase I/II Clinical Evaluation of StrataGraft: A Consistent, Pathogen-Free Human Skin Substitute. *Journal of Trauma-Injury Infection and Critical Care*. 2009; 66(3):866–873.
22. Okah FA, Wickett RR, Pickens WL, Hoath SB. Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. *Pediatrics*. 1995; 96(4 Pt 1):688–92. [PubMed: 7567331]
23. Boyce ST, Supp AP, Harriger MD, et al. Surface electrical capacitance as a noninvasive index of epidermal barrier in cultured skin substitutes in athymic mice. *J Invest Dermatol*. 1996; 107(1):82–7. [PubMed: 8752844]
24. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol*. 1984; 133(4):1710–5. [PubMed: 6206131]
25. Patel GK, Wilson CH, Harding KG, et al. Numerous keratinocyte subtypes involved in wound re-epithelialization. *J Invest Dermatol*. 2006; 126(2):497–502. [PubMed: 16374449]
26. Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis. *J Dermatol Sci*. 2000; 24(Suppl 1):S29–38. [PubMed: 11137393]

27. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. *Immunol Today*. 1994; 15(10): 464–9. [PubMed: 7945770]
28. Mutlu S, Matthews JB, Midda M, et al. MHC antigen expression in human oral squamous carcinoma cell lines. *J Pathol*. 1991; 165(2):129–36. [PubMed: 1744799]
29. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. *J Invest Dermatol*. 1984; 83(2):88–90. [PubMed: 6206165]
30. Denfeld RW, Hollenbaugh D, Fehrenbach A, et al. CD40 is functionally expressed on human keratinocytes. *Eur J Immunol*. 1996; 26(10):2329–34. [PubMed: 8898941]
31. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. *J Interferon Res*. 1985; 5(1):23–32. [PubMed: 3921630]
32. Volc-Platzer B, Leibl H, Luger T, et al. Human epidermal cells synthesize HLA-DR alloantigens in vitro upon stimulation with gamma-interferon. *J Invest Dermatol*. 1985; 85(1):16–9. [PubMed: 3159800]
33. Peguet-Navarro J, Dalbiez-Gauthier C, Moulon C, et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. *J Immunol*. 1997; 158(1):144–52. [PubMed: 8977185]
34. Skoskiewicz MJ, Colvin RB, Schneeberger EE, Russell PS. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. *J Exp Med*. 1985; 162(5):1645–64. [PubMed: 3932581]
35. Ross W, Hall PA. Ki67: from antibody to molecule to understanding? *Clin Mol Pathol*. 1995; 48(3):M113–M117. [PubMed: 16695990]
36. Camidge DR, Davies MJ, Laud PJ, et al. Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies. *Cancer Chemother Pharmacol*. 2006; 57(1):52–8. [PubMed: 16032432]
37. Gilhar A, Ullmann Y, Karry R, et al. Aging of human epidermis: reversal of aging changes correlates with reversal of keratinocyte fas expression and apoptosis. *J Gerontol A Biol Sci Med Sci*. 2004; 59(5):411–5. [PubMed: 15123749]
38. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. *Transplantation*. 2008; 85(11):1513–22. [PubMed: 18551047]
39. Obhrai JS, Oberbarnscheidt M, Zhang N, et al. Langerhans cells are not required for efficient skin graft rejection. *J Invest Dermatol*. 2008; 128(8):1950–5. [PubMed: 18337832]
40. Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. *Annu Rev Immunol*. 1983; 1:143–73. [PubMed: 6443557]
41. Bowen KM, Lafferty KJ. Reversal of diabetes by allogenic islet transplantation without immunosuppression. *Aust J Exp Biol Med Sci*. 1980; 58(5):441–7. [PubMed: 6786275]
42. Caballero A, Fernandez N, Lavado R, et al. Tolerogenic response: allorecognition pathways. *Transpl Immunol*. 2006; 17(1):3–6. [PubMed: 17157204]
43. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. *Transpl Immunol*. 2002; 10(2-3):101–8. [PubMed: 12216939]
44. Lafferty KJ, Bootes A, Dart G, Talmage DW. Effect of organ culture on the survival of thyroid allografts in mice. *Transplantation*. 1976; 22(2):138–49. [PubMed: 61634]
45. Jacobs BB. Ovarian allograft survival. Prolongation after passage in vitro. *Transplantation*. 1974; 18(5):454–7. [PubMed: 4432270]
46. Lueker DC, Sharpton TR. Survival of ovarian allografts following maintenance in organ culture. *Transplantation*. 1974; 18(5):457–8. [PubMed: 4473850]
47. Laning JC, DeLuca JE, Hardin-Young J. Effects of immunoregulatory cytokines on the immunogenic potential of the cellular components of a bilayered living skin equivalent. *Tissue Eng*. 1999; 5(2):171–81. [PubMed: 10358223]

48. Daynes RA, Emam M, Krueger GG, Roberts LK. Expression of Ia antigen on epidermal keratinocytes after the grafting of normal skin to nude mice. *J Immunol.* 1983; 130(4):1536–9. [PubMed: 6339613]
49. Krueger GG, Daynes RA, Roberts LK, Emam M. Migration of Langerhans cells and the expression of Ia on epidermal cells following the grafting of normal skin to nude mice. *Exp Cell Biol.* 1984; 52(1-2):97–102. [PubMed: 6230272]
50. Laning JC, DeLuca JE, Isaacs CM, Hardin-Young J. In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T-cell response to allogeneic “nonprofessional” antigen presenting cells. *Transplantation.* 2001; 71(10):1467–1474. [PubMed: 11391237]
51. Nickoloff BJ, Basham TY, Merigan TC, et al. Human keratinocyte-lymphocyte reactions in vitro. *J Invest Dermatol.* 1986; 87(1):11–8. [PubMed: 2941488]
52. Ledbetter JA, Imboden JB, Schieven GL, et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. *Blood.* 1990; 75(7):1531–9. [PubMed: 2156582]
53. Muhart M, McFalls S, Kirsner R, et al. Bioengineered skin. *Lancet.* 1997; 350(9085):1142. [PubMed: 9343505]
54. Falanga V, Margolis D, Alvarez O, et al. Human Skin Equivalent Investigators Group. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. *Arch Dermatol.* 1998; 134(3):293–300. [PubMed: 9521027]
55. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. *Dermatol Surg.* 1995; 21(10):839–43. [PubMed: 7551738]
56. Volc-Platzer B, Majdic O, Knapp W, et al. Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. *J Exp Med.* 1984; 159(6):1784–9. [PubMed: 6202820]
57. Aubock J, Romani N, Grubauer G, Fritsch P. HLA-DR expression on keratinocytes is a common feature of diseased skin. *Br J Dermatol.* 1986; 114(4):465–72. [PubMed: 2421756]
58. Griffiths M, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. *Tissue Engineering.* 2004; 10(7-8):1180–1195. [PubMed: 15363174]
59. Eaglstein WH, Alvarez OM, Auletta M, et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). *Dermatol Surg.* 1999; 25(3):195–201. [PubMed: 10193966]
60. Phillips TJ, Manzoor J, Rojas A, et al. The longevity of a bilayered skin substitute after application to venous ulcers. *Arch Dermatol.* 2002; 138(8):1079–81. [PubMed: 12164746]
61. Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. *Wound Repair Regen.* 2006; 14(4):427–33. [PubMed: 16939570]
62. Piontek GE, Taniguchi K, Ljunggren HG, et al. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. *J Immunol.* 1985; 135(6):4281–8. [PubMed: 3905967]
63. Harel-Bellan A, Quillet A, Marchiol C, et al. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. *Proc Natl Acad Sci U S A.* 1986; 83(15):5688–92. [PubMed: 2426704]
64. Quillet A, Presse F, Marchiol-Fournigault C, et al. Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells. *J Immunol.* 1988; 141(1):17–20. [PubMed: 3288697]
65. Storkus WJ, Howell DN, Salter RD, et al. NK susceptibility varies inversely with target cell class I HLA antigen expression. *J Immunol.* 1987; 138(6):1657–9. [PubMed: 3819393]
66. Karlhofer FM, Ribaldo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. *Nature.* 1992; 358(6381):66–70. [PubMed: 1614533]
67. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. *Immunol Today.* 1990; 11(7):237–44. [PubMed: 2201309]
68. Theobald VA, Lauer JD, Kaplan FA, et al. Neutral allografts”—lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. *Transplantation.* 1993; 55(1):128–33. [PubMed: 8093564]
69. Thivolet J, Faure M, Demidem A, Mauduit G. Long-term survival and immunological tolerance of human epidermal allografts produced in culture. *Transplantation.* 1986; 42(3):274–80. [PubMed: 3750385]

70. Rothermel AL, Wang Y, Schechner J, et al. Endothelial cells present antigens in vivo. *BMC Immunol.* 2004; 5(1):5. [PubMed: 15113397]

Figure 1.

In vitro-generated tissues have characteristics comparable to those of native skin. (A) H&E stained sections from NIKS and NHEK skin substitutes, and human neonatal foreskin tissue, exhibit typical epidermal morphology, containing a single layer of basal cells, beneath stratified spinous, granular, and cornified layers. Scale bar = 50 μ m. (B) Barrier function was measured using a Nova DermaPhase meter (DPM) which measures skin surface electrical impedance in arbitrary units. DPM values reflect electrical impedance and are inversely related to surface hydration, therefore, lower DPM values indicate a dryer surface. Tissues made from NIKS (StrataGraft) or NHEK exhibit barrier function comparable to that of native human skin. The values obtained for intact skin and skin where the barrier function has been disrupted by tape stripping are presented as controls. Data represent mean $\pm$ SEM. (C) Antibodies specific to type I transglutaminase (TG), filaggrin, and collagen IV (Coll IV) were used to examine the differentiation pattern present in NIKS and NHEK tissues and human neonatal foreskin. Grey scale images for each protein examined are shown. Color-merged images display sections counterstained with Hoechst 33258 to visualize nuclei (blue). Scale bars = 50 μ m. (D) Expression of MHC antigens was also assessed (grey scale), with color-merged images depicting HLA-ABC in red, HLA-DR in green, and Hoechst 33258 in blue. Scale bars = 50 μ m.

Figure 2.

Overview of clinical trial design. Fifteen patients with full-thickness skin defects of 5% total body surface area were surgically debrided and wound beds were covered with StrataGraft and cadaver allografts placed adjacent to each other. Allografts were removed after one week and processed for histologic analysis. Patients were autografted when the wound beds were deemed by the clinician to be suitable for autografting. The primary efficacy endpoint was the percent of autograft take two weeks after autograft placement. A panel of secondary safety and efficacy analyses were performed at baseline, one week after allograft placement, and after three months.

Figure 3.

StrataGraft skin substitute remains intact and viable after placement in the wound bed. (A) Representative paraffin-embedded H&E-stained sections of StrataGraft and cadaver allografts after removal from the wound bed of two different patients. Scale bar = 50 μ m. (B). Representative images of StrataGraft and cadaver allograft samples stained for Ki67 expression after removal from the wound beds of two different patients reveal Ki67 staining of viable cells present in basal and suprabasal layers (brown). Scale bar = 50 μ m. (C) Sections were assessed by two blinded observers and basal keratinocytes were scored as positive or negative for Ki67 staining. At least 400 cells from each sample were counted and the proliferation index (PI) (ratio of positive cells to the total cells counted) was determined. Shown are paired StrataGraft and cadaver allograft sample PI values from eight individual patients. The bar indicates the median value. McNemar's test, $P = 0.13$.

Figure 4.

StrataGraft skin substitute does not exhibit acute inflammatory infiltrates. Representative images of StrataGraft and cadaver allografts removed from the wound beds of two different patients, stained (brown) for CD3 to indicate T cell infiltrates, CD20 as a marker of B lymphocytes, and CD1 α to identify Langerhans cells. Scale bars = 100 μ m.

Figure 5.

HLA-ABC, but not HLA-DR, is expressed in the basal and suprabasal epidermal keratinocytes of both StrataGraft and cadaver allografts after placement in the wound bed. The expression and localization of HLA-ABC and HLA-DR was assessed by immunofluorescence. Shown are representative grey scale and color images of post-placement StrataGraft and cadaver skin allografts stained for HLA-ABC (A; shown in red) and HLA-DR (B; shown in green) after removal from the wound beds of 2 different patients. Nuclei were counterstained with Hoechst 33258 (blue). Scale bar = 100 μ m.

Table 1

Patient PBMC proliferation in response to NIKS cells

Patient number		Proliferation assay (stimulation index*)						
		10 ⁴ NIKS cells		10 ⁵ NIKS cells				
		pretreatment	post-treatment	pretreatment	post-treatment			
								3 day
Cohort 1: up to 0.5% TBSA		1	6	9	6	6	6	(−)
			1	3	0	3	3	
		2	7	2	11	5	5	(−)
			4	0	5	0	0	
		3	0	1	0	1	1	(−)
			0	0	0	0	0	
		4	1	2	1	1	1	(−)
			1	3	1	3	3	
		5	9	1	7	4	4	(−)
			1	1	0	0	0	
Cohort 2: up to 1.0% TBSA		6	2	9	15	10	10	(−) [†]
			0	9	2	8	8	
		7	6	9	5	36	36	(−) [†]
			4	5	2	10	10	
		8	1	10	5	9	9	(−) [†]
			0	1	1	2	2	
		9	1	1	1	1	1	(−)
			0	0	0	0	0	
		10	2	1	2	0	0	(−)
			5	1	4	1	1	

Patient number	Proliferation assay (stimulation index [*])					
	10 ⁴ NIKS cells		10 ⁵ NIKS cells			
	pretreatment	post-treatment	pretreatment	post-treatment		
	3 day	6 day	3 day	6 day	3 day	6 day
Cohort 3: up to 1.5% TBSA	11	1	1	1	1	1
		1	1	0	1	
	12	2	1	2	1	
		2	1	0	0	
	13	1	7	1	3	
		4	2	1	1	
	14	1	2	3	1	
		1	1	1	1	
	15	2	1	1	0	
		0	0	0	0	

(+) indicates a positive proliferation response; (-) indicates a negative proliferation response

^{*} Stimulation Index = counts per treatment / counts in the media

[‡] Very low level ³H-TdR incorporation in background and NIKS samples. All counts are <3,500 and thus the changes in the stimulation indices are not considered biologically significant or indicative of in vivo sensitization.

Table 2
Patient PBMC cytotoxicity against NIKS cells

Patient number	Cytotoxicity assay (% cytotoxicity for 50:1 E:T)		
	Pretreatment	Post-treatment	(+/-)
Cohort 1: up to 0.5% TBSA	1	4	5.1
	2	11.9	5.5
	3	7.1	18.6
	4	4	3.5
	5	31.6	45.6
Cohort 2: up to 1.0% TBSA	6	3.2	8.7
	7	8.8	24
	8	25.1	6.1
	9	2.1	6.5
	10	-1.8	3.8
Cohort 3: up to 1.5% TBSA	11	3.1	2.8
	12	N/T [‡]	-1
	13	-1.9	-4.1
	14	3.6	3
	15	6.7	7.3

(+) indicates a positive cytotoxic response; (-) indicates a negative cytotoxic response;

(+/-) indicates that a positive response is not ruled out

* All increases in % cytotoxicity values over baseline are less than 20% even at the 50:1 effector to target ratio for patients 1 and 3 and less than 10% for patient 6. Furthermore, the level of cytotoxicity does not decrease with the dilution of effector cells so these changes are not considered biologically significant or indicative of *in vivo* sensitization.

[†] Patients 5 and 7 had the highest pre sample cytotoxicity values compared to all patients entered in the trial. Their post-treatment values slightly increased from their pretreatment values. This increase may be within day-to-day variability of this assay but some level of *in vivo* sensitization can not be ruled out.

[‡] N/T = not tested

Table 3

MHC class I panel reactive antibody (PRA) results

Cohort #	Patient # gender	Mode of injury	% TBSA	% TBSA treated	Day	Class I PRA %	Antibody specificities detected	Blood product transfused
1: up to 0.5% TBSA	1 male	MVC-degloving	5	0.5	0	0		
					7	NT		
					90	0		
	2 male	MVC-burn	17.5	0.3	0	0		PRC, FFP [¶]
					7	0		PRC, FFP [¶]
					90	0		
	3 female	Thermal burn	6	0.3	0	0		
					7	10 [*]		
					90	46	B7,27 B35,52,57,+	
	4 male	Thermal burn	16	0.3	0	3		PRC [¶]
7					28	B8,14,18,39+	PRC [¶]	
90					36	B8,14,18,39,35,45,51+		
5 male	Thermal burn	13	0.3	0	0			
				7	0			
				90	0			
2: up to 1.0% TBSA	6 female	Necrotizing Fasciitis	8	0.6	0	70	Multiple [§]	PRC ^G
					7	90	Multiple [§]	PRC ^G
					90	97	Multiple [§]	
	7 emale	Necrotizing Fasciitis	15	0.9	0	2		PRC, FFP, PLT [¶]
					7	13	B7	PRC, FFP, PLT ^{**}
					90	0		
	8 male	Explosion-burn	73	0.9	0	10		PRC [¶]
7					7		PRC ^{**}	

Cohort #	Patient # gender	Mode of injury	% TBSA	% TBSA treated	Day	Class I PRA %	Antibody specificities detected	Blood product transfused
3: up to 1.5% TBSA	9 male	Explosion-burn	12	0.9	90	2		PRC**
					0	0		
					7	0		
	10 male	Explosion-burn	25	0.6	90	0		
					0	0		PRC [†]
					7	0		PLT [‡]
	11 female	Thermal burn	13	0.9	90	0		
					0	0		
					7	0		PRC [‡]
	12 male	Electrical-burn	17.5	1.2	90	0		
					0	0		
					7	NT		
3: up to 1.5% TBSA	13 male	Explosion-burn	42.5	1.5	90	0		
					0	0		PRC [†]
					7	17	[†] B35,39	PRC [‡]
	14 male	Thermal burn	31	1.5	90	0		
					0	0		PRC, FFP [‡]
					7	0		PRC, FFP [‡]
	15 male	Thermal burn	38.5	1.5	90	0		
					0	0		
					7	0		PRC [‡]
	Mean ± SD		22.2 ± 18.0		90	0		
						10.0 ± 23.4		

TBSA, total body surface area; PRC, packed red blood cells; FFP, fresh frozen plasma; PLT, platelets; NT, not tested; PTD, post-treatment day; day 0, treatment application; day 7 ± 24 hr, removal of allografts; day 90 ± 1 wk, study completion

* Patient had a wound bed infection at the time of allograft removal confirmed by quantitative culture at PTD 7

[†]Weakly positive

[‡]NIKS keratinocytes are HLA-B51

[§]Too many reactive cells to reliably detect the antibody specificities

[¶]Patient received a blood transfusion on the date of the blood draw for PRA

// Patient received a blood transfusion several days prior to the date of the blood draw for PRA

^{**} Patient received a blood transfusion within a month prior to the date of the blood draw for PRA